KESTRA MEDICAL TECHNOLOGIES, LTD. — Form 8-K
Filed July 14, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 62/100
What the filing says
Kestra Medical Technologies reported FY26 revenue of $95.1M (up 59% YoY) with gross margin expanding to 51.4% from 40.5%, driven by 20,720 ASSURE system prescriptions. The company guided FY27 revenue to $137M (44% growth). Despite strong top-line growth, the company posted a net loss of $131.6M (vs. $113.8M prior year) and adjusted EBITDA loss of $87.0M (vs. $68.4M), with cash and investments of $262.2M as of April 30, 2026.
Why this rating
Strong revenue growth and margin expansion are positive, but mounting losses and continued cash burn offset gains. Material relative to ~$379M asset base.
See more from July 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.